- 1 Integrated genomic and histopathological analysis of low grade serous ovarian carcinoma
- 2 identifies clinically distinct disease subtypes
- 3 John P Thomson^{1a}, Robert L Hollis^{1a}, Juliette van Baal^{2a}, Narthana Ilenkovan¹, Michael
- 4 Churchman¹, Koen van de Vijver², Frederike Dijk³, Alison M Meynert⁴, Clare Bartos¹, Tzyvia
- 5 Rye¹, Ian Croy¹, Patricia Diana¹, Mignon van Gent³, Helen Creedon⁵, Rachel Nirsimloo⁵, Fiona
- 6 Nussey⁵, Christianne Lok^{2b}, C. Simon Herrington^{1,b} and Charlie Gourley^{1,b}
- ¹Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre,
- 8 MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
- ²Department of Gynaecologic Oncology and Department of Pathology, The Netherlands Cancer
- 10 Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands
- ³Department of Gynaecologic Oncology and Department of Pathology, Amsterdam University
- 12 Medical Centres, Amsterdam, The Netherlands
- ⁴MRC Human Genetics Unit, MRC Institute of Genetics and Cancer, University of Edinburgh,
- 14 Edinburgh, UK

- ⁵Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
- 16 a,b Authors contributed equally
- 18 Corresponding Author(s): Professor Charlie Gourley Nicola Murray Centre for Ovarian
- 19 Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGC, University of Edinburgh.
- 20 Crewe Road South, Edinburgh, EH4 2XU, UK. email: charlie.gourley@ed.ac.uk.

Abstract

25

26

30

34

46

51

52

Background.

- 27 Low-grade serous ovarian carcinoma (LGSOC) is a distinct, under-investigated and relatively
- 28 chemotherapy-resistant ovarian cancer type. Understanding the molecular landscape is crucial
- 29 to maximise the impact of molecularly-targeted therapy.

Methods

- 31 Whole exome sequencing and copy number data were integrated with histopathological patterns,
- 32 ER/PR expression, and detailed clinical annotation, including survival, in a carefully curated
- 33 LGSOC cohort.

Results

- 35 63 tumours were analysed in the largest comprehensive genomic LGSOC study to date. Three
- 36 genomic subgroups were identified: canonical MAPK mutant (cMAPKm: 52%
- 37 KRAS/BRAF/NRAS), MAPK-associated mutation (27%, 14 MAPK-associated genes) and MAPK
- 38 wild-type (MAPKwt: 21%). MAPKwt patients were younger at diagnosis (median 47 versus 62
- 39 years in the cMAPKm subgroup) and demonstrated shorter survival [multivariable HR (mHR)
- 40 4.17]. The inferior survival in the MAPKwt subgroup was due to shorter post-relapse survival
- 41 (mHR 5.22) rather than shorter time to first progression (mHR 1.15). Patients in the MAPK-
- 42 associated mutation subgroup had similar survival to cMAPKm cases. The cMAPKm subgroup
- 43 more frequently demonstrated macropapillary invasion. Desmoplasia and micropapillary invasion
- 44 were independently associated with poor survival. NOTCH pathway activation occurred
- 45 independently of MAPK subgroup.

Conclusions

- 47 LGSOC comprises multiple genomic subgroups with distinct clinical, molecular and
- 48 histopathological features. True MAPKwt cases represent around a fifth of patients: they are
- 49 younger but have poorer survival. New therapeutic strategies with activity in this subgroup are
- urgently required. NOTCH inhibitors represent a therapeutic strategy worthy of exploration.

Introduction

Low grade serous ovarian carcinoma (LGSOC) is an uncommon (<5%) and under-investigated ovarian cancer type, in some cases arising from serous borderline tumours [1]. In contrast to high grade serous ovarian cancers (HGSOCs), LGSOCs are *TP53* wild-type, do not demonstrate genomic instability or homologous recombination repair deficiency and frequently harbour classical activating mutations in canonical MAPK pathway components (*KRAS*, *BRAF* and *NRAS*) [2-5]. LGSOCs typically display high oestrogen receptor (ER) expression, with expression of progesterone receptor (PR) in a subset of cases [6].

LGSOC often affects younger women (median 47 years) [7]. The response rate to platinum-based chemotherapy is 5-25% [8, 9], compared to 70-80% in HGSOCs. Relapsed LGSOC follows a more indolent course than relapsed HGSOC, demonstrating prolonged post-relapse survival [10, 11]. Appreciation of LGSOC as a separate entity has driven a management shift away from the conventional 'one size fits all' approach to ovarian cancer treatment, with endocrine therapy showing significant activity [12, 13]. Recently, the MEK inhibitor trametinib also demonstrated notable efficacy, delaying disease progression in the context of LGSOC recurrence compared to standard of care therapies [14, 15]. Another MEK inhibitor binimetinib, while not demonstrating superiority to standard of care chemotherapy, did show an overall response rate of 16% with a suggestion that patients whose tumours harboured activating KRAS mutations were more likely to respond [16].

Until recently, genomic characterisation of LGSOC had been limited to targeted sequencing of selected genes [3, 4, 17-19] or whole exome sequencing of a small number of cases (n=8, n=9, n=22) [5, 17, 20]. Most recently, a targeted sequencing study of 71 LGSOC cases [19] identified mutation of *KRAS*, *BRAF* or *NRAS* in 47% of cases, alongside further less common potentially actionable mutations.

Here we investigate whether comprehensive genomic characterisation of LGSOC can be implemented to stratify LGSOC cases into clinically meaningful subgroups. We perform whole exome sequencing (WES) on tumour material from 63 LGSOC patients, identifying genomic subgroups centred around the MAPK pathway. These subgroups demonstrate significant differences in patient age, clinical outcome and histopathological features; we identify patient groups more likely to experience long-term survival, and highlight high-risk patient groups for which new treatment strategies are required to improve outcome.

Methods

85

86

92

105

Ethical approval

- 87 Ethical approval was obtained from the Lothian Human Annotated Bioresource (reference
- 88 15/ES/0094-SR925), NKI-AVL Translational Research Board (reference CFMPB284), and
- University of Amsterdam AMC Biobank Assessment Committee (reference 2016_070#A201641).
- 90 All participants provided written informed consent or had consent waived by the ethics committee
- 91 due to the retrospective nature of the study.

Cohort identification and pathology review

- 93 Cases were identified from local databases. All cases underwent expert gynaecological
- 94 pathology review (KvdV, CSH). Cases were excluded if: WT1 negative; aberrant p53
- 95 expression; no definitive stromal invasion; *TP53* gene mutation.

96 Assessment of histopathological patterns in LGSOC

- 97 H&E-stained sections underwent secondary review to identify the presence of desmoplasia and
- 98 the macropapillary (MaP) and micropapillary (MiP) patterns of invasion[22]. MaP was defined as
- 99 stromal invasion by papillary structures containing fibrovascular cores[22]; MiP was defined as
- invasion by papillary structures without fibrovascular cores.

101 Clinical data

- 102 Baseline patient characteristics, treatment information and outcome data were retrieved from
- local databases and from patient file review. Disease-specific survival (DSS) was calculated from
- the date of confirmed ovarian cancer (OC) diagnosis.

Whole exome sequencing, variant calling and analysis

- 106 Following DNA extraction from macrodissected FFPE sections (Supplementary Methods 1),
- 107 exome capture was performed using the Illumina TruSeg Exome Library Prep kit and WES was
- 108 performed on the Illumina NextSeq 550 (Illumina, Inc., San Diego, CA, USA). Samples failed
- 109 sequencing QC if mean on-target coverage was <30X. Data were aligned to the GRCh38 human
- reference genome using bwa-0.7.17[29], duplicates marked and base quality scores recalibrated
- with the GenomeAnalysisToolkit (GATK) v4[30] within the bcbio 1.0.6 pipeline (Supplementary
- 112 Methods 2). Variants were called using a majority vote system from three callers (VarDict[31],
- 113 Mutect2[32] and Freebayes[33]) and were filtered to remove common and likely non-functional
- 114 variation. Analysis of variants and oncogenic pathways was performed using the R package
- maftools[34]. Functional tumour mutational burden (fTMB) was calculated as the number of
- mutations present following filtering. CNV analysis was carried out using a custom script utilising
- the Python package multiBamSummary, comparing read normalised 10kb binned scores
- 118 between in house "normal" buffy coat derived sample datasets and LGSOC samples. For more
- information on these analyses see Supplementary Methods 3-6.

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141142

Immunohistochemistry for ER and PR Immunohistochemistry for ER and PR was performed using protocol F on the Leica BOND III Autostainer (Supplementary Methods 7). ER immunohistochemistry used rabbit anti-ER antibody M3643 clone EP1; PR immunohistochemistry used mouse anti-PR antibody M3569 clone PgR-636. Nuclear expression was quantified using histoscore, generated by multiplying the proportion of positive tumour nuclei (0 - 100%) by the intensity of nuclear staining (0 - 3) to produce weighted scores from 0 to 300[35]. Two independent observers scored digital images of stained slides, demonstrating excellent agreement (rho=0.96 for PR, rho=0.93 for ER) (Supplementary Methods 7). Final patient histoscore was calculated as the mean score of the two observers. Statistical analysis Statistical analyses were performed using R version 4.0.3. The Mann Whitney-U test or T-test were used to compare continuous data, as appropriate. Survival analyses were performed using the Cox proportional hazards regression analysis in the Survival package. Univariable survival analyses are presented as hazard ratios (HRs) alongside 95% confidence intervals. Multivariable analyses are presented similarly, detailing multivariable hazard ratios (mHRs). Median follow-up time was calculated using the reverse Kaplan-Meier method. Comparisons of frequency were performed using the Chi-squared test or Fisher's exact test, as appropriate. Data availability The genomic data presented in this manuscript are being made available via deposition in the European Genome-Phenome Archive.

Results

143

144

153

172

173

Cohort characteristics

- 145 118 LGSOC cases were identified. 41 cases were excluded for insufficient tumour material or
- 146 cellularity; 3 failed DNA quality control; 5 had insufficient sequencing coverage. 69 cases
- 147 underwent genomic characterisation by WES. 6 cases harbouring TP53 mutations were
- excluded as potential occult HGSOC, leaving 63 cases in the final LGSOC study cohort (Figure
- 149 S1). The median per-sample on-target coverage in the study cohort was 64X (range 32X-132X).
- 150 Clinical characteristics of the LGSOC study cohort are summarized in Table 1. The median
- 151 follow-up time was 13.3 years. All patients underwent cytoreductive surgery. The median
- disease-specific survival (DSS) was 12.9 years.

Genomic features identify subgroups of low grade serous ovarian carcinoma

- 154 WES identified canonical MAPK pathway mutations in 33 cases (52.4%) (cMAPKm subgroup):
- 155 24 KRAS (38.1%), 6 BRAF (9.5%) and 3 NRAS (4.8%) (Figures 1, S2, S3), which occurred
- mutually exclusively. The majority of these events occurred at known mutational hotspots (83%
- 157 of KRAS G12R/C/D/V, 100% BRAF V600E, 100% NRAS Q61R/K) (Figure S4).
- Pathway analysis of mutated genes revealed a further 17 cases (27.0%) with perturbation of the
- 159 MAPK/RAS pathway by mutations across 14 other MAPK-associated genes defined by the
- 160 TCGA PanCanAtlas [21] (MAPK-associated mutations) (Figures 1 S5). These events were
- 161 largely mutually exclusive (co-occurrence in 1 case), and genomic events in these genes seldom
- occurred in cMAPKm cases (co-occurrence in 2 cases). The total frequency of MAPK/RAS
- pathway alteration was 50 of 63 cases (79.4%) (33 cMAPKm, 17 MAPK-associated mutations).
- 164 A further 13 cases were MAPK wild-type (MAPKwt). These patients demonstrated significantly
- younger age at diagnosis compared to cMAPKm cases (median 47 vs 62 years, P=0.048)
- 166 (Figures 1, 2A & Table S1).
- 167 NOTCH pathway perturbation was also common (21.0% of cases), occurring both in the context
- of MAPK/RAS pathway alteration (34.0%, 17/50) and in MAPKwt cases (30.8%, 4/13) (Figure
- S5). Recurrent gene targets of mutation beyond MAPK pathway components included ATM (5
- 170 cases, 7.9%), USP9X (5 cases, 7.9%) and EIF1AX (3 cases, 4.8%) (Figures 1, S3). There was
- significant co-occurrence between NRAS and EIF1AX mutation (P=0.005).

Copy number alterations in low grade serous carcinoma

- Across the cohort, loss of all or part of chromosome 19 (chr19) was common (22 cases (34.9%):
- p and q arms; 6 cases (9.5%): p arm; 2 cases (3.2%): q arm). Chr19p loss was most frequent in
- 177 MAPKwt cases (9 of 13 cases, 69.2%), but this was not statistically significantly higher than in
- the cMAPKm group (P=0.056) (Figure S6).
- Gain of the q arm of chr1 occurred in 19 cases (30.2%), while loss of the p arm of chr1 occurred
- in 13 cases (20.6%). Gain of the q arm of chr8 was also common (16 cases, 25.4%). In
- agreement with previous reports, four cases (6.3%) demonstrated copy number loss specifically
- 182 over the USP9X locus.

174

183

184

Histopathological patterns in low grade serous carcinoma

- A MiP pattern of invasion was identified in 38 cases (60.3%), while a MaP invasion pattern was
- identified in 23 cases (36.5%) (Figure 1)[22]. The MiP and MaP patterns were largely mutually
- 187 exclusive (P<0.0001, co-occurrence in only 3 cases). 5 cases demonstrated neither MaP nor MiP
- pattern. The MaP pattern was more common in cMAPKm cases (54.5%) compared to MAPKwt
- 189 (23.1%; p=0.004; Figure 2B).
- 190 Desmoplasia was identified in 40 cases (63.5%). Desmoplasia was associated with advanced
- stage at diagnosis (92.5%, 37 of 40 desmoplastic cases with FIGO III/IV vs 50.0%, 11 of 22
- 192 evaluable non-desmoplastic cases with FIGO III/IV; P<0.001). Desmoplasia was also associated
- 193 with the presence of macroscopic RD (67.5%, 27 of 40 desmoplastic cases demonstrated
- macroscopic RD vs 33.3%, 14 of 21 evaluable non-desmoplastic cases, P=0.015) (Figures 2C,
- 195 3A, 3B).

196

197

206

ER and PR expression in low grade serous carcinoma

- 198 LGSOC samples stained uniformly for ER (histoscore ≥50 in 60 of 61 evaluable cases, 98.4%; 2
- non-evaluable) (Figure S7A). Median ER and PR histoscores were 220 (range 7.5-300) and 50
- 200 (range 0-295) respectively (Figure S7A and S7B). Analysis of ER and PR levels across the
- 201 genomic classes revealed higher levels of PR expression in the MAPKwt subgroup (median PR
- 202 histoscore 105) (Figure 2D, Figure S7C), but this was not significantly higher compared to the
- 203 cMAPKm and MAPK-associated subgroups (median PR histoscore 45 and 35, P=0.083).
- 204 Desmoplastic tumours demonstrated significantly lower PR expression (median histoscore 30 vs
- 205 110, Bonferroni-adjusted P=0.003) (Figure 3C) than non-desmoplastic tumours.

Features associated with outcome in low grade serous carcinoma

- 208 Patients with LGSOC demonstrating desmoplasia experienced significantly shorter DSS (HR for
- 209 no desmoplasia 0.18, 95% CI 0.05-0.62) (Figures 4A, S8A); the MiP pattern was also associated
- with poor DSS (HR for absence of MiP 0.29, 95% CI 0.10-0.86) (Figures 4B, S8B). Conversely,
- 211 high PR expression was associated with significantly prolonged survival (HR for PR histoscore
- 212 ≥50 0.23, 95% CI 0.09-0.60) (Figures 4C, S8C).
- 213 Multivariable analysis of LGSOC features (genomic subgroup, PR status, MiP pattern and
- 214 desmoplasia) accounting for clinicopathological variables identified the MAPKwt subgroup
- 215 (multivariable HR [mHR] for cMAPKm vs MAPKwt 0.24, 95% CI 0.07-0.79), desmoplastic cases
- 216 (mHR for absence of desmoplasia 0.20, 95% CI 0.04-0.89) and the MiP pattern (mHR for
- 217 absence of MiP=0.27, 95% CI 0.08-0.91) as independently associated with shorter DSS (Figure
- 4D, Table S2). PR status was not independently associated with significantly longer DSS (mHR
- 219 0.38, 95% CI 0.12-1.14).

207

- 220 Further endpoint analysis suggested that inferior DSS in the MAPKwt group was due to shorter
- post-relapse survival (mHR 5.22, 95% CI 1.20-22.67) rather than rapid disease progression
- 222 following first-line treatment (mHR 1.15, 95% CI 0.43-3.08).

Discussion

- 224 LGSOC affects younger women than HGSOC and demonstrates greater intrinsic
- chemoresistance. Although survival is better than HGSOC, patients frequently relapse resulting
- 226 in morbidity from largely ineffectual therapies and premature mortality. As such, better
- 227 (molecular) characterization and new therapies are urgently required.
- 228 Few studies have performed molecular characterisation of robustly curated LGSOC cohorts.
- Where molecular profiling studies have been performed, these have been limited to panel based
- sequencing of selected genes [3, 18, 19], or have included only a small number of patient
- samples [5, 20]. Few of these studies have used immunohistochemistry for WT1/p53 to confirm
- 232 LGSOC diagnosis. Here we report comprehensive genomic profiling by WES, integrating these
- 233 data with histopathological analysis, clinical data and assessment of ER and PR expression
- 234 patterns in a sizeable LGSOC cohort.
- 235 52% of cases harboured mutations in the canonical MAPK pathway components KRAS, BRAF
- and NRAS. This cMAPKm group more frequently demonstrated the MaP pattern of invasion,
- 237 represented older patients (median 62 years) and was associated with more favourable DSS and
- 238 post-relapse survival. These data are consistent with previously reported favourable survival in
- 239 LGSOC patients with tumours harbouring KRAS or BRAF mutations identified by targeted
- 240 sequencing [3]. Our data suggest that this survival benefit is due to prolonged post-relapse
- 241 survival.

243

244

245246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

While the rate of cMAPKm within our LGSOC cohort (52%) is similar to that reported in previous targeted sequencing studies [17, 19] and WES of small LGSOC cohorts [20], we also identified a further 27% of cases (MAPK-associated group) demonstrating mutational disruption of genes related to the MAPK pathway [21]; these cases demonstrated a survival profile similar to that of the cMAPKm cases. The remaining MAPKwt cases (21%) represented patients with younger age at diagnosis (median 47 years) and who experienced shorter survival. This suggests that previous observations of poorer survival in younger LGSOC patients may be underpinned by differences in disease biology between younger and older patients [23]. MAPKwt cases often demonstrated the MiP pattern of invasion (62%), with only 23% demonstrating the MaP pattern. While different histopathological patterns of invasion (MaP and MiP) were associated with the genomic subgroups, we demonstrate that the MiP pattern is independently associated with shorter survival time (mHR 3.76). We also demonstrate that the presence of desmoplasia is associated with poorer outcome (mHR 5.10), independent of its relationship with more advanced stage disease and residual disease status. Both the GOG281/LOGS and MILO studies suggested that the response rates to MEK inhibition were greater in patients with canonical MAPK defects [14, 16]. However, to date, no assessment of relative MEK inhibitor efficacy has been made with regard to MAPK pathway mutations beyond KRAS/BRAF/NRAS; future work should seek to quantify efficacy within these patients, and should determine whether patients with no identifiable genomic MAPK defect (MAPKwt) derive any benefit from MEK inhibition. Beyond the MAPK pathway, analysis of genomic events from our WES data suggest perturbation of the NOTCH signalling pathway is common, affecting a notable proportion of cases both with and without MAPK defects (34% and 31%, respectively). NOTCH pathway inhibition may therefore represent a novel therapeutic strategy for LGSOC patients with intrinsic or acquired resistance to chemotherapy and/or MEK inhibitors. We report the first investigation using WES in a sizeable LGSOC cohort (n=63) with detailed clinical annotation and extensive follow-up. The use of immunohistochemistry for WT1 and p53 status to robustly curate our cohort, represents a major strength of this work. However, while our dataset represents one of the largest LGSOC collections reported to date, the overall cohort size remains modest due to the rarity of LGSOC. Confirmatory studies characterising the behaviour of the described genomic subgroups, and associations with age, histopathological features and outcome, are therefore required. Collectively, our data identify a subgroup of LGSOC with mutations in MAPK pathway components beyond KRAS, BRAF and NRAS. Alongside the cMAPKm subgroup, these cases demonstrate more favourable outcome when compared to MAPKwt patients, who are younger at

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

diagnosis. The MaP pattern of invasion is a potential histopathological indicator of cMAPKm LGSOC. Desmoplasia and the MiP pattern are features independently associated with survival. **Acknowledgements** Funding: RLH was supported by Target Ovarian Cancer. This work was funded in part by a HANARTH Foundation grant. We extend our thanks to The Nicola Murray Foundation for their generous support of The Nicola Murray Centre for Ovarian Cancer Research. JT and CB were supported by core funding from the CRUK Edinburgh Centre. AMM was supported by core funding awarded to the MRC Human Genetics Unit. We are grateful to the NHS Lothian Department of Pathology, Edinburgh Experimental Cancer Medicine Centre, the Edinburgh Ovarian Cancer Database and the NRS Lothian Human Annotated Bioresource for their ongoing support. The high throughput sequencing described here was supported by the Edinburgh Clinical Research Facility, Western General Hospital, Edinburgh, UK. We would like to acknowledge the NKI- AVL Core Facility Molecular Pathology & Biobanking (CFMPB) for supplying NKI-AVL Biobank material and providing laboratory support. **Declaration of interest statement:** RLH: consultancy fees from GlaxoSmithKline. FN: non-personal interests in AstraZeneca and Tesaro, CG: research funding from Roche, AstraZeneca, Novartis, Aprea, Nucana, GSK, Tesaro, BerGen Bio, Medannexin, Verastem; honoraria/consultancy fees Roche, AstraZeneca, MSD, GSK, Tesaro, Nucana, Clovis, Foundation One, Chugai, Sierra Oncology, Cor2Ed and Takeda; named on issued/pending patents related to predicting treatment response in ovarian cancer outside the scope of the work described here. All other authors declare no conflicts of interest.

References

- 301 [1] Shih le M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological
- and molecular genetic analysis. Am J Pathol. 2004;164:1511-8.
- 303 [2] Cheasley D, Nigam A, Zethoven M, Hunter S, Etemadmoghadam D, Semple T, et al.
- Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J Pathol. 2020.
- 306 [3] Gershenson DM, Sun CC, Wong KK. Impact of mutational status on survival in low-grade
- serous carcinoma of the ovary or peritoneum. Br J Cancer. 2015;113:1254-8.
- 308 [4] Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, et al. Molecular
- 309 profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
- 310 Oncotarget. 2015;6:37663-77.
- 311 [5] Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, et al. Low-grade
- serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012;226:413-20.
- 313 [6] Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-
- receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium
- 315 study. Lancet Oncol. 2013;14:853-62.
- 316 [7] Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, et al. Impact of Age
- 317 and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the
- Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. J Clin
- 319 Oncol. 2015;33:2675-82.
- 320 [8] Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, et al. Operability
- and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of
- the AGO Study Group metadatabase. Gynecol Oncol. 2016;140:457-62.
- 323 [9] Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, et al.
- Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol
- 325 Oncol. 2008;108:510-4.
- [10] Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, et al. Clinical behavior
- of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361-8.
- 328 [11] Irodi A, Rye T, Herbert K, Churchman M, Bartos C, Mackean M, et al. Patterns of
- 329 clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of
- prospectively collected data. Bjog. 2020;127:1409-20.
- 331 [12] Gershenson DM. Current advances in the management of malignant germ cell and sex cord-
- 332 stromal tumors of the ovary. Gynecol Oncol. 2012;125:515-7.
- 333 [13] Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal
- 334 Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J
- 335 Clin Oncol. 2017;35:1103-11.
- 336 [14] Gershenson DM, Miller A, Brady W, Paul J, Carty K, Rodgers W, et al. LBA61 A
- 337 randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or
- progressive low-grade serous ovarian or peritoneal cancer. Annals of Oncology. 2019;30:v897v8.
- [15] Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, et al. Trametinib versus
- standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a
- randomised, open-label phase 2/3 trial. The Lancet. In press.
- [16] Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, et al. MILO/ENGOT-
- ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-
- 345 Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol.
- 346 2020;38:3753-62.
- 347 [17] Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, et al. Molecular
- 348 profiling of low grade serous ovarian tumours identifies novel candidate driver genes.
- 349 Oncotarget. 2015;6:37663-77.
- 350 [18] Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, et al.
- 351 Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS
- pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clinical cancer
- research: an official journal of the American Association for Cancer Research. 2014;20:6618-30.
- [19] Cheasley D, Nigam A, Zethoven M, Hunter S, Etemadmoghadam D, Semple T, et al.
- 355 Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic
- vulnerabilities. The Journal of pathology. 2021;253:41-54.

- 357 [20] Etemadmoghadam D, Azar WJ, Lei Y, Moujaber T, Garsed DW, Kennedy CJ, et al. EIF1AX
- and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.
- 359 Cancer Res. 2017;77:4268-78.
- 360 [21] Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic
- 361 Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173:321-37.e10.
- 362 [22] Yemelyanova A, Mao TL, Nakayama N, Shih IM, Kurman RJ. Low-grade serous carcinoma
- of the ovary displaying a macropapillary pattern of invasion. Am J Surg Pathol. 2008;32:1800-6.
- 364 [23] Gershenson DM, Bodurka DC, Lu KH, Nathan LC, Milojevic L, Wong KK, et al. Impact of age
- and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or
- 366 peritoneum: Results of a large single-institution registry of a rare tumor. Journal of Clinical
- 367 Oncology. 2015;33:2675-82.
- 368 [24] Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, et al. Low-grade
- serous ovarian cancer: State of the science. Gynecol Oncol. 2020;156:715-25.
- 370 [25] Gershenson DM. Low-grade serous carcinoma of the ovary or peritoneum. Ann Oncol.
- 371 2016;27 Suppl 1:i45-i9.
- 372 [26] Langdon SP, Herrington CS, Hollis RL, Gourley C. Estrogen Signaling and Its Potential as a
- Target for Therapy in Ovarian Cancer. Cancers (Basel). 2020;12.
- 374 [27] Marchetti C, De Felice F, Ergasti R, Scambia G, Fagotti A. Letrozole in the management of
- advanced ovarian cancer: an old drug as a new targeted therapy. Int J Gynecol Cancer.
- 376 2020;30:1058-64.
- 377 [28] Gershenson DM, Sun CC, Iyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, et al. Hormonal
- therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol.
- 379 2012;125:661-6.
- 380 [29] Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform.
- 381 Bioinformatics (Oxford, England). 2010;26:589-95.
- 382 [30] McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome
- Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.
- 384 Genome research. 2010;20:1297-303.
- 385 [31] Lai Z, Markovets A, Ahdesmaki M, Chapman B, Hofmann O, McEwen R, et al. VarDict: a
- novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic
- 387 Acids Res. 2016;44:e108.
- 388 [32] Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive
- detection of somatic point mutations in impure and heterogeneous cancer samples. Nat
- 390 Biotechnol. 2013;31:213-9.
- 391 [33] Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. arXiv
- 392 preprint. 2012;arXiv:1207.3907 [q-bio.GN].
- 393 [34] Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and
- comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747-56.
- 395 [35] Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, et al. Observer
- 396 variation in immunohistochemical analysis of protein expression, time for a change?
- 397 Histopathology. 2006;48:787-94.

Table 1. Clinical characteristics of low grade serous ovarian carcinoma cases.

		N	%
Cases	Total	63	
Age	Median	54 years	Range 19-66
Centre	Edinburgh Cancer Centre	31	49.2
	University of Amsterdam Academic Medical Centre	10	15.9
	Netherlands Cancer Institute	22	34.9
FIGO stage	1	9	14.5
	II	5	8.1
	III	39	62.9
	IV	9	14.5
	NA	1	-
RD following cytoreduction	Macroscopic RD	34	55.7
	No macroscopic RD	27	44.3
	Unknown RD status	2	-
Neoadjuvant chemo	No	48	76.2
	Yes	15	23.8
Macropapillary invasion pattern	No	40	63.5
	Yes	23	36.5
Micropapillary invasion pattern	No	25	29.7
	Yes	38	60.3
Desmoplasia	No	23	36.5
	Yes	40	63.5
Diagnosis period	Pre-2000	10	15.9
	2000s	24	38.1
	2010 onward	29	46.0
Death details at last follow-up	Alive	25	39.7
	Died of OC	21	33.3
	Died of other causes	9	14.3
	Died, unknown cause	8	12.7
Outcome	5-year DSS	70.6%	95% CI 59.1-84.4
	Median follow-up	13.3 years	95% CI 6.36-NA

FIGO, International Federation of Gynecology and Obstetrics; NA, not available; RD, residual disease; OC, ovarian carcinoma; DSS, disease-specific survival




Figure 1: Molecular landscape of low grade serous ovarian carcinoma. fTMB, functional tumour mutational burden; Ti, transitions; Tv, transversions; SNV, single nucleotide variant; CNV, copy number variant; cMAPKm, canonical MAPK pathway mutation (KRAS/BRAF/NRAS); MAPK-assoc, MAPK-associated mutation; MAPKwt, MAPK pathway wild-type.




Figure 2. Characteristics of genomic subgroups in low grade serous ovarian carcinoma. (A) Patient age at diagnosis across genomic subgroups; labelled P value represents the comparison between the canonical MAPK mutation (cMAPKm) group and the MAPK wild-type (MAPKwt) group. (B) Histopathological patterns across genomic subgroups; labelled P value represents comparison of MaP frequency in cMAPKm versus subgroups by Chi-squared test. (C) Desmoplasia across genomic subgroups; labelled P value represents comparison of desmoplasia frequency between all subgroups by Chi-squared test. (D) Progesterone receptor (PR) expression across genomic subgroups; labelled P value represents comparison of MAPKwt group versus other subgroups by Mann Whitney-U test. MiP: micropapillary; MaP: macropapillary. No des = no desmoplasia identified.




Figure 3. Features associated with desmoplasia in low grade serous ovarian carcinoma. (A) Distribution of stage at diagnosis between tumours with and without desmoplasia. (B) Distribution of stage at diagnosis between tumours with and without desmoplasia. (C) Progesterone receptor (PR) expression between cases with and without desmoplasia. Desmo = desmoplastic; No des = no desmoplasia identified; zero RD = zero macroscopic residual disease after debulking surgery; macro RD = macroscopic residual disease after debulking surgery.




Figure 4. Impact of low grade serous ovarian carcinoma features on disease-specific survival. (A) Disease-specific survival (DSS) of patients with tumours demonstrating desmoplasia. (B) DSS of patients with tumours demonstrating the micropapillary (MiP) pattern of invasion. (C) DSS of patients with tumours expressing progesterone receptor (PR). (D) Forest plot summarising multivariable survival analysis of low grade serous ovarian carcinoma features. HR, hazard ratio; 95% CI, 95% confidence interval; mHR, multivariable HR; no des, no desmoplasia identified; RD, residual disease; cMAPKm, canonical MAPK pathway mutation (KRAS/BRAF/NRAS); MAPK-assoc, MAPK-associated mutation; MAPKwt, MAPK pathway wild-type.